118. Oligos: new synthesis technologies

Oligonucleotides are moving beyond rare diseases—but scaling them is anything but simple. As therapies target larger patient populations, new synthesis technologies must stand up to real‑world manufacturing constraints, regulatory scrutiny, cost pressures and sustainability demands.

In this episode of Discovery Matters, industry experts explore what it really takes to make oligos at scale. From the limits of legacy synthesis methods to the promise - and risk - of data, automation and AI, they unpack why progress depends on mastering fundamentals before accelerating innovation.

The takeaway? The future of oligos isn’t just better science. It’s smarter, scalable and collaborative manufacturing—built to reliably deliver life‑changing medicines to patients.